Drug Trial Radar · NCT05263739
A First-in-Human Phase I Study of ESG206 in Subjects With B-cell Lymphoid Malignancies
Last checked: Nov 19, 2026Latest source record: Sep 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Dec 2025
Primary completion
Aug 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Shanghai Escugen Biotechnology Co., LtdIndustry
- Sponsor type
- Industry
- Collaborators
- Escugen (Australia) Biotechnology Pty Ltd
- First posted
- Mar 3, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a first-in-human phase I, multicenter, open label, sequential-cohort, dose escalation study of ESG206. The purpose is to evaluate the clinical safety, tolerability, PK, and preliminary efficacy and to establish the MTD, if any, and RP2D(s) of ESG206 in adult subjects with B lymphoid malignancies.
Conditions
- B-cell Lymphoid Malignancies
Interventions
ESG206Drug
Administered via intravenous (IV) infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Experiencing Any Treatment Emergent Adverse EventsTime frame: First dose date up to last dose plus 30 days
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.